Tonix Pharmaceuticals Holding Corp. released an investor presentation outlining its focus areas in CNS, infectious disease, immunology and rare disease, and reporting approximately $208 million in cash as of Dec. 31, 2025 with no debt and an expected cash runway into Q1 2027. The deck highlights the company’s marketed products, including TONMYA for fibromyalgia and the migraine treatments TOSYMRA and ZEMBRACE SymTouch, and provides commercial details for TONMYA, including reported net sales of $1.4 million for the period Nov. 17 to Dec. 31, 2026, a field sales force of about 90 representatives, and a patient access program. The presentation also lists TONMYA wholesale acquisition cost prices of $1,860 for a 60-count prescription and $930 for a 30-count prescription. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 01, 2026, and is solely responsible for the information contained therein.